Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats.
about
Pregnancy in women with thalassemia: challenges and solutionsPharmacogenetic study of deferasirox, an iron chelating agentAutoradiography, MALDI-MS, and SIMS-MS imaging in pharmaceutical discovery and development.Systemic iron chelation results in limited functional and histological recovery after traumatic spinal cord injury in rats.Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function.Self-assembled penetratin-deferasirox micelles as potential carriers for hydrophobic drug delivery.Potential clinical applications of chelating drugs in diseases targeting transferrin-bound iron and other metals.Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia.Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia.Clinical pharmacology of deferasirox.Deferasirox-TAT(47-57) peptide conjugate as a water soluble, bifunctional iron chelator with potential use in neuromedicine.Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients.Treatment of Myelofibrosis: Old and New Strategies.Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats.Role of pharmacogenetics on deferasirox AUC and efficacy.Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment.Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients.Deferasirox associated with liver failure and death in a sickle cell anemia patient homozygous for the -1774delG polymorphism in the Abcc2 geneInfluence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness.Iron-chelation therapy with oral chelators in patients with thalassemia major.Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes.A record of 1320 suspect, deferasirox-related, patient deaths reported in 2009: insufficient toxicity testing, low efficacy and lack of transparency may endanger the lives of iron loaded patients.Determination of deferasirox plasma concentrations: do gender, physical and genetic differences affect chelation efficacy?Deferasirox-induced serious adverse reaction in a pediatric patient: pharmacokinetic and pharmacogenetic analysis.
P2860
Q28080216-944CC292-0B07-4377-81EC-8C11F5F8F176Q28533457-F1444B6E-A09E-442C-902C-06E157143633Q30890487-8EE364A8-4851-424E-9440-8B1CB0D496C2Q33888020-A3D3FB2A-A8F7-42F6-B6DC-5C1F2E1E321EQ35088183-A548C8FB-F511-4D77-9E32-C09DF6D9D6B7Q35631409-502851D6-6CD3-48E5-99B1-ACC1B3046A06Q38099045-89BCA76E-A626-43B2-8958-F89FA4FF4B38Q38148200-2257AD2E-F54B-4179-A5CB-38798BEFDCE2Q38219588-7A38B6A5-EDB6-4121-A84D-5BFD52A4D702Q38226394-C4347EA4-6433-4745-97FC-DCE719246B36Q38854241-F5A4B06E-71B7-406E-BAC4-DE84E7AA027EQ38874222-EBEF146A-49C6-4E95-8A0E-6604DC762AD1Q39349869-36669B47-7E86-43E5-8A71-1092434C370BQ39775863-DECF789D-DB5F-4DE8-91F8-CDF00F330734Q39865051-15720E53-41E3-472B-A222-C9D3F7E84FEAQ40499884-D394A6A7-17C4-4A73-8EA4-5D82583A78ACQ40657471-F44F721F-D1D9-4136-9E97-FEAEF24E437FQ41196701-4A9BF82D-884A-4AFC-A400-BD7D88C79BA2Q41687355-8BD21B5D-0915-4133-AEA1-6CBEE14A5B64Q45753026-ED936A10-6DD2-47DA-B971-BC8769198CFAQ48263712-BE6432A8-A74D-4814-8851-58A452A8BB57Q48665941-5F40F2BB-68F0-4274-B619-2A333E7B53D7Q51123803-F4401D63-2F81-413C-B127-0C30DFACBB57Q53816619-0E8FA22D-A600-4728-8AF6-4A360EC21FA3
P2860
Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Pharmacokinetics, distribution ...... and its iron complex in rats.
@en
Pharmacokinetics, distribution ...... and its iron complex in rats.
@nl
type
label
Pharmacokinetics, distribution ...... and its iron complex in rats.
@en
Pharmacokinetics, distribution ...... and its iron complex in rats.
@nl
prefLabel
Pharmacokinetics, distribution ...... and its iron complex in rats.
@en
Pharmacokinetics, distribution ...... and its iron complex in rats.
@nl
P2093
P356
P1476
Pharmacokinetics, distribution ...... and its iron complex in rats.
@en
P2093
Alain Schweitzer
Felix Waldmeier
Gerard J M Bruin
Hansjörg Wiegand
Hanspeter Nick
Josef Schneider
K-Olaf Boernsen
Thomas Faller
P304
P356
10.1124/DMD.108.022962
P577
2008-09-05T00:00:00Z